BACKGROUND: Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition, mHSPC, and those who relapse after prior local therapy (PLT) have longer overall survival (OS) compared to high volume (HV) and de-novo (DN), respectively. Using a hospital-based registry, we aimed to assess whether a classification based on time of metastatic disease (PLT vs DN) and disease volume (LV vs HV) are prognostic for mHSPC pts treated with ADT. METHODS: A retrospective cohort of consecutive patients with mHSPC treated with ADT between 1990 and 2013 was selected from the prospectively collected Dana-Farber Cancer Institute database and categorized as DN or PLT and HV or LV, at time of ADT start. Primary and secondary endpoints were OS and time to castration-resistant prostate cancer (CRPC), respectively, which were measured from date of ADT start using Kaplan-Meier method. Multivariable Cox proportional hazards models using known prognostic factors was used. RESULTS: The analytical cohort consisted of 436 patients. The median OS and time to CRPC for PLT/LV were 92.4 (95%CI: 80.4-127.2) and 25.6 (95%CI: 21-35.7) months and 43.2 (95%CI: 37.2-56.4) and 12.2 (95%CI: 9.8-14.8) months for DN/HV, respectively, whereas intermediate values were observed for PLT/HV and DN/LV. A robust gradient for both outcomes was observed (Trend test P < 0.0001) in the four groups. In a multivariable analysis, DN presentation, HV, and cancer-related pain were independent prognostic factors. CONCLUSIONS: In our hospital-based registry, time of metastatic presentation and disease volume were prognostic for mHSPC pts treated with ADT. This simple prognostic classification system can aid patient counseling and future trial design.
BACKGROUND: Currently, there is no universally accepted prognostic classification for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT). Subgroup analyses demonstrated that pts with low volume (LV), per CHAARTED trial definition, mHSPC, and those who relapse after prior local therapy (PLT) have longer overall survival (OS) compared to high volume (HV) and de-novo (DN), respectively. Using a hospital-based registry, we aimed to assess whether a classification based on time of metastatic disease (PLT vs DN) and disease volume (LV vs HV) are prognostic for mHSPCpts treated with ADT. METHODS: A retrospective cohort of consecutive patients with mHSPC treated with ADT between 1990 and 2013 was selected from the prospectively collected Dana-Farber Cancer Institute database and categorized as DN or PLT and HV or LV, at time of ADT start. Primary and secondary endpoints were OS and time to castration-resistant prostate cancer (CRPC), respectively, which were measured from date of ADT start using Kaplan-Meier method. Multivariable Cox proportional hazards models using known prognostic factors was used. RESULTS: The analytical cohort consisted of 436 patients. The median OS and time to CRPC for PLT/LV were 92.4 (95%CI: 80.4-127.2) and 25.6 (95%CI: 21-35.7) months and 43.2 (95%CI: 37.2-56.4) and 12.2 (95%CI: 9.8-14.8) months for DN/HV, respectively, whereas intermediate values were observed for PLT/HV and DN/LV. A robust gradient for both outcomes was observed (Trend test P < 0.0001) in the four groups. In a multivariable analysis, DN presentation, HV, and cancer-related pain were independent prognostic factors. CONCLUSIONS: In our hospital-based registry, time of metastatic presentation and disease volume were prognostic for mHSPCpts treated with ADT. This simple prognostic classification system can aid patient counseling and future trial design.
Authors: Emilie Lalonde; Adrian S Ishkanian; Jenna Sykes; Michael Fraser; Helen Ross-Adams; Nicholas Erho; Mark J Dunning; Silvia Halim; Alastair D Lamb; Nathalie C Moon; Gaetano Zafarana; Anne Y Warren; Xianyue Meng; John Thoms; Michal R Grzadkowski; Alejandro Berlin; Cherry L Have; Varune R Ramnarine; Cindy Q Yao; Chad A Malloff; Lucia L Lam; Honglei Xie; Nicholas J Harding; Denise Y F Mak; Kenneth C Chu; Lauren C Chong; Dorota H Sendorek; Christine P'ng; Colin C Collins; Jeremy A Squire; Igor Jurisica; Colin Cooper; Rosalind Eeles; Melania Pintilie; Alan Dal Pra; Elai Davicioni; Wan L Lam; Michael Milosevic; David E Neal; Theodorus van der Kwast; Paul C Boutros; Robert G Bristow Journal: Lancet Oncol Date: 2014-11-13 Impact factor: 41.316
Authors: Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes Journal: N Engl J Med Date: 2017-06-03 Impact factor: 91.245
Authors: Kyo Chul Koo; Sang Un Park; Ki Hong Kim; Koon Ho Rha; Sung Joon Hong; Seung Choul Yang; Byung Ha Chung Journal: Yonsei Med J Date: 2015-09 Impact factor: 2.759
Authors: Eberhard Varenhorst; Rami Klaff; Anders Berglund; Per Olov Hedlund; Gabriel Sandblom Journal: Cancer Med Date: 2016-01-14 Impact factor: 4.452
Authors: Philip W Kantoff; Wassim Abida; Konrad H Stopsack; Subhiksha Nandakumar; Andreas G Wibmer; Samuel Haywood; Emily S Weg; Ethan S Barnett; Chloe J Kim; Emily A Carbone; Samantha E Vasselman; Bastien Nguyen; Melanie A Hullings; Howard I Scher; Michael J Morris; David B Solit; Nikolaus Schultz Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: E M Kwan; I A Thangasamy; J Teh; O Alghazo; N J Sathianathen; N Lawrentschuk; A A Azad Journal: World J Urol Date: 2020-01-02 Impact factor: 4.226
Authors: Fernando Cotait Maluf; Felipe Moraes Toledo Pereira; Pedro Luiz Serrano Uson; Diogo Assed Bastos; Diogo Augusto Rodrigues da Rosa; Evanius Garcia Wiermann; Fábio A Schutz; Fábio Roberto Kater; Fernando Nunes Galvão de Oliveira; Fernando Sabino Marques Monteiro; Fernando Vidigal de Pádua; Francisco Javier Orlandi; Helena Paes de Almeida Saito; Mouna Ayadi; Pamela Salman Boghikian; Ray Manneh Kopp; Ricardo Saraiva de Carvalho; Rodrigo Nogueira de Fogace; Sandro Roberto de Araújo Cavallero; Sergio Aguiar; Vinicius Carreira Souza; Silke Gillessen Sommer Journal: JCO Glob Oncol Date: 2021-04
Authors: Carlo Cattrini; Elena Castro; Rebeca Lozano; Elisa Zanardi; Alessandra Rubagotti; Francesco Boccardo; David Olmos Journal: Cancers (Basel) Date: 2019-09-12 Impact factor: 6.639
Authors: Maria Elisabeth Lendorf; Peter Meidahl Petersen; Andrea Steen Svendsen; Henriette Lindberg; Klaus Brasso Journal: Eur Urol Open Sci Date: 2021-01-06
Authors: Edoardo Francini; Francesco Montagnani; Pier Vitale Nuzzo; Miguel Gonzalez-Velez; Nimira S Alimohamed; Pietro Rosellini; Irene Moreno-Candilejo; Antonio Cigliola; Jaime Rubio-Perez; Francesca Crivelli; Grace K Shaw; Li Zhang; Roberto Petrioli; Carmelo Bengala; Guido Francini; Jesus Garcia-Foncillas; Christopher J Sweeney; Celestia S Higano; Alan H Bryce; Lauren C Harshman; Richard Lee-Ying; Daniel Y C Heng Journal: JAMA Netw Open Date: 2021-07-01